{
    "nctId": "NCT04897009",
    "briefTitle": "Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer",
    "officialTitle": "Evaluating the Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Patients With Operable Breast Cancer (ENHANCE)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Invasive Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 38,
    "primaryOutcomeMeasure": "Association of peripheral blood immune phenotypes with pathological complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Histologically confirmed, operable, invasive breast cancer. Note: Patients with oligometastatic breast cancer (up to 3 isolated distant metastases) will be eligible after review and approval by principal investigator (PI)\n* Recommended to receive neoadjuvant systemic treatment by their primary medical oncologist and planning to receive one of the regimens\n* Provide written informed consent\n* Willing to return to Mayo Clinic for breast cancer surgery\n* Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic\n\nExclusion Criteria:\n\n* Patients who have already initiated neoadjuvant chemotherapy for the current malignancy\n* Inability to provide blood samples based on the judgement of the treating physician\n* Inability to comply with the protocol\n* Patient is pregnant or plans to become pregnant",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}